4d Molecular Therapeutics, INC Form 4 insider transactions

John F. Milligan, a Director at 4D Molecular Therapeutics, Inc., was granted 33,750 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, acquired stock options for 78,500 shares at an exercise price of $4.14 on March 6, 2025.

4D Molecular Therapeutics CEO David Kirn was granted stock options to purchase 267,500 shares of common stock on March 6, 2025.

Robert Young Kim, Chief Medical Officer of 4D Molecular Therapeutics, was granted stock options for 92,300 shares at an exercise price of $4.14 on March 6, 2025.

Uneek Mehra, Chief Financial & Business Officer of 4D Molecular Therapeutics, reports the acquisition of stock options.

Fariborz Kamal, President & COO of 4D Molecular Therapeutics, acquired stock options for 178,400 shares on March 6, 2025.

RA Capital Healthcare Fund exchanged 535,000 shares of 4D Molecular Therapeutics common stock for pre-funded warrants exercisable for the same number of shares at a nominal price.

BVF Partners and related entities exchanged 5.775 million shares of 4D Molecular Therapeutics common stock for an equal number of pre-funded warrants.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

CEO David Kirn of 4D Molecular Therapeutics reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

David Kirn, CEO of 4D Molecular Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Shawn Tomasello acquired 22,500 stock options in 4D Molecular Therapeutics on May 21, 2024, according to a recent SEC filing.

Director Jacob Chacko acquired 22,500 stock options in 4D Molecular Therapeutics on May 21, 2024, as part of the company's non-employee director compensation program.

Director Charles Theuer acquired 22,500 stock options in 4D Molecular Therapeutics on May 21, 2024, as part of the company's non-employee director compensation program.

Director Nancy Miller-Rich of 4D Molecular Therapeutics reports the acquisition of stock options as part of the company's non-employee director compensation program.

Director John F. Milligan reports the acquisition of stock options in 4D Molecular Therapeutics.

Susannah Gray, a director of 4D Molecular Therapeutics, acquired 22,500 stock options on May 21, 2024, as part of the company's non-employee director compensation program.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.